WE AIM FOR AN ACTIVE LIFESTYLE AND IMPROVED QUALITY OF LIFE FOR THE MILLIONS AFFECTED BY CHRONIC INFLAMMATORY DISEASES
MORE ABOUT US

WE DEVELOP AN ANTI-INFLAMMATORY DRUG WITH FIRST-IN-CLASS POTENTIAL

We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.

Lipum also address the treatment of Juvenile Iodiopathic Artrithis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.

THE STORY BEHIND LIPUM

Lipum was originally founded based on a discovery made by sci­entists at Umeå University.

The history of the innovation goes back 25 years when Olle Hernell, Prof. of Pediatrics, and his group was studying the nutrition of breast milk in newborns during early infancy, focusing on a protein that is now known as bile salt-stimulated lipase (BSSL).

Read more
For privacy reasons YouTube needs your permission to be loaded.
I Accept

CEO EINAR PONTÉN AT REDEYE INITIATE

Live Broadcast where Einar Pontén presents Lipum and the progress towards clinical trials.

Watch on Youtube

GROWING UP WITH JUVENILE IDIOPATHIC ARTHRITIS

Every year more than 200 Swedish children are diagnosed with juvenile idiopathic arthritis (JIA), also known as childhood arthritis, a rheumatic disease that affects the joints and can cause severe pain. For those affected the disease can cause considerable suffering and result in a reduced quality of life. To gain a greater understanding of how JIA affects young people we have spoked with Clara Laurell, who has lived with the disease for several years.

Read more
SUBSCRIBE TO INFORMATION FROM LIPUM

NEWS

News: Umeå, 9 August 2022. Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation...
News: Umeå, 8 July, 2022. Lipum (publ) is preparing for the start of its first in human phase 1 clinical trial and the team is now strengthened with...
Press release: Umeå, 17 June 2022. Lipum (publ) reports that the GLP toxicology- and safety program on the candidate drug (SOL-116) has been completed...

PRESS RELEASES

Press release: Umeå, 27 July, 2022. Lipum AB has published the interim report for period January to June 2022. Below is a short summary, a complete...
Press release: Umeå, 18 May 2022. Lipum AB (publ) has published the interim report for period January to March for 2022. Below is a summary, a complete...
Press release: Umeå, 25 March 2022. Lipum AB (publ) has published the interim report for period October to December and the year-end report for 2021...